A Case of Complete Clinical Response with Sorafenib in a Patient with Thyroid Gland Metastases from Renal Cell Carcinoma 17 Years from Diagnosis

Benincasa, Elena; Conti, Alessandra; Bossone, Giandominik; Gallà, Domenico Antonio Pasquale; Gianciotta, Antonio; Zuccaro, Stefano Maria; Madaio, Raffaele

doi:10.1177/030089160909500325

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only 4 cases have been described in detail, with additional cases reported with limited description. [7][8][9] A recent report discussed the possibility of achieving CR by combining neoadjuvant sorafenib with surgical resection. 10 TKIs may induce partial carcinoma shrinkage and substitution with necrotic-fibrotic tissue, allowing easier resection of smaller, limited lesions.…”

Section: Discussionmentioning

confidence: 99%

Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report

Murata

Naoe

Ogawa

et al. 2013

CUAJ

View full text Add to dashboard Cite

We present a case of a patient with metastatic renal cell carcinoma (mRCC) who was treated solely with low-dose sorafenib and achieved a complete response (CR). A 79-year-old man with cytokine-refractory mRCC involving the lung, abdominal wall and lymph nodes was treated with low-dose sorafenib (400 mg/day) as a second-line therapy. Five months into treatment, CR was confirmed by follow-up computed tomography. No severe adverse events were observed and sorafenib treatment was continued without appearance of new lesions. Although sorafenib has been approved for mRCC treatment, complete clinical recovery is uncommon and has rarely been described. In this case, low-dose sorafenib appears to be sufficient for achieving CR while suppressing toxicity. Furthermore, long-term continuous administration induces the patient to obtain disease stabilization. However, considering toxicity and treatment costs, it is debatable whether treatment should be discontinued or sustained after CR.

show abstract